NCT02845089已完成不适用
Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates
Bristol-Myers Squibb0 个研究点目标入组 382 人开始时间: 2016年2月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 382
- 主要终点
- Duration of systemic treatments
研究概览
简要总结
A retrospective observational longitudinal medical chart review study of randomly sampled patients diagnosed with advanced/metastatic NSCLC. The minimum observational period for each patient will be 12 months.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults 18 years and older at the time of advanced/metastatic NSCLC diagnosis, and currently alive or deceased
- •Histologically confirmed diagnosis of advanced/metastatic NSCLC (squamous, non-squamous or NOS) stages IIIB/IV. First diagnosis of advanced/metastatic NSCLC between 01-Jan-2010 and 31-Mar-2014 (currently alive or deceased) with a minimum 12 months of potential observation period available in medical records
- •Medical history and treatment data must be available (or obtainable by SI) for chart abstraction from the date of advanced/metastatic diagnosis through most recent patient follow-up/contact. This also includes documentation of treatment by other physicians and inpatient hospital treatments within KSA or the Health Authority of Abu Dhabi (HAAD) system
- •Patients must have at least all data on age, gender, date of advanced NSCLC diagnosis, Line of Treatment (LOT) information (agent types and dosage), and date of last follow-up
排除标准
- •Patient had enrolled in a cancer treatment-related clinical study at any time after the diagnosis of advanced/metastatic NSCLC
结局指标
主要结局
Duration of systemic treatments
时间窗: approximately 12 months
Patient Demographics at diagnosis with advanced/metastatic NSCLC
时间窗: at baseline
Systemic treatments prescribed for NSCLC patients from treatment initiation through discontinuation
时间窗: approximately 12 months
Distribution of reasons for discontinuing treatment
时间窗: approximately 12 months
次要结局
- Overall Survival (OS)(approximately 12 months)
- Adverse Events (AEs)(approximately 12 months)
- healthcare resource utilization in patients with advanced/metastatic NSCLC(approximately 12 months)
- Progression-Free Survival (PFS)(approximately 12 months)
研究者
相似试验
已完成
不适用
Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung CancerNon-small Cell Lung Cancer NSCLCSmall Cell Lung Cancer SCLCLung CancerNCT03505515Bristol-Myers Squibb6,205
已完成
不适用
Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCCRenal Cell Carcinoma MetastaticRenal Cell CarcinomaNCT03699579Ipsen28
已完成
不适用
A Retrospective Study of Treatment Patterns and Clinical Outcomes in Patients With Central Nervous System TuberculosisCentral Nervous System TuberculosisNCT06011915Tongji Hospital638
已完成
不适用
A Research Study, Looking at the Characterization of Treatment Intensified (Add on to Metformin) Real-world Adult Population With Type 2 Diabetes Mellitus in India, Pakistan and Thailand.Diabetes Mellitus, Type 2NCT05542420Novo Nordisk A/S3,000
终止
不适用
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and OutcomesBreast CancerNCT04396626Pfizer975